Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-HCC Trial
2020-004210-35Phase 3Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Time to failure of treatment strategy (TTFS). Started Dec 2020; status: active.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-004210-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004210-35.